Market news

BeOne Medicines has delivered an 86.0% gain over the past three years, yet current valuation checks point to a stock that screens as overvalued on market multiples and only mixed on broader metrics. Recent regulatory wins and a higher share price leave investors weighing a strong track record against a less clear-cut value case. BeOne Medicines is up 86.0% over three years, which makes the stock more dependent on whether the business can now justify that stronger share price profile. FDA...

BeOne Medicines recently secured U.S. FDA approvals for TEVIMBRA and ZIIHERA-based regimens in first-line HER2-positive gastroesophageal cancers and entered a voluntary agreement with the U.S. government to expand access to its oncology drugs while investing more than US$1.00 billion in U.S. manufacturing. This combination of first-in-class immunotherapy approval and U.S. tariff exemption tied to onshoring commitments reshapes BeOne’s positioning in cancer care and its cost base in a key...

BeOne Medicines AG (NASDAQ:ONC) entered a voluntary agreement with the U.S. government that combines pharmaceutical-tariff protection with commitments on manufacturing, Medicaid participation, and the pricing of future medicines. The agreement gives BeOne Medicines AG (NASDAQ:ONC) an exemption from Section 232 pharmaceutical tariffs while recognizing more than $1 billion of U.S. manufacturing investment, including a $300 […]

On August 25, BeOne Medicines (NASDAQ:ONC) said the FDA approved TEVIMBRA in combination with ZIIHERA and chemotherapy as a first-line treatment for HER2-positive gastroesophageal adenocarcinoma, a hard-to-treat cancer that strikes more than 31,000 Americans a year. The approval rests on Phase 3 data showing patients lived a median of 26.4 months, more than two years, […]

SAN CARLOS, Calif., September 01, 2026--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley Annual Global Healthcare Conference on September 14, 2026, with a fireside chat at 11:30 a.m. EDT.

Trump unveils new drug-pricing deals with pharma and biotechs to cut U.S. healthcare costs, with Medicaid most-favored-nation pricing.

SAN CARLOS, Calif., August 31, 2026--BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scient

BeOne Medicines (ONC) voluntarily agreed with the US government to expand patient access to its canc

Detailed price information for Biogen Inc (BIIB-Q) from The Globe and Mail including charting and trades.

Jazz Pharmaceuticals (JAZZ) stock rises as the FDA approves the company's cancer therapy developed with BeOne Medicines (ONC) and Zymeworks (ZYME). Read more here.

Is it a good or bad thing when a stock experiences a golden cross technical event?

SAN CARLOS, Calif. & SEATTLE, August 18, 2026--BeOne Medicines Ltd. ("BeOne") (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with t

BeOne Medicines (ONC), the BeOne Care Foundation, and The Max Foundation have renewed their partners

Two oncology powerhouses, BeOne Medicines AG (NASDAQ:ONC) and Revolution Medicines, Inc. (NASDAQ:RVMD), announced a major multi-part clinical collaboration and regional licensing deal. Under the August 10 agreement, the companies will combine select clinical-stage assets from BeOne with Revolution’s four clinical-stage RAS(ON) inhibitors to evaluate novel combination therapies for RAS-addicted cancers. Crucially, BeOne acquired exclusive rights […]

Motley Fool Press Release.

BeOne Medicines Ltd (ONC) delivers robust Q2 2026 results with record BRUKINSA sales, raises full-year guidance, and advances a promising oncology pipeline.

In early August 2026, BeOne Medicines Ltd. and Revolution Medicines, Inc. announced a multi-part collaboration combining BeOne’s oncology assets with Revolution’s four clinical RAS(ON) inhibitors, alongside a regional licensing deal granting BeOne exclusive development and commercialization rights in select Asian markets and responsibility for funding a global Phase 3 trial. This arrangement gives Revolution Medicines access to BeOne’s development “superhighway,” milestone and royalty...

Revolution Medicines (RVMD) just entered a comprehensive partnership with BeOne Medicines that combines joint clinical development work and a regional rights deal in select Asian markets for its RAS(ON) oncology inhibitors. See our latest analysis for Revolution Medicines. The BeOne Medicines partnership lands at a time when Revolution Medicines has already seen strong momentum, with a 90 day share price return of 37.09% and year to date share price return of 160.12%, alongside a very large 1...

Revolution Medicines (NASDAQ:RVMD) just picked up a partner with deep pockets and a presence across Asia. On August 10, the company announced a multi-part collaboration with BeOne Medicines, pairing clinical development with a regional rights deal. For a stock that has already climbed more than 400% over the past year, the question is whether this […]

The partnership will focus on developing combination therapies for patients with RAS-addicted cancers.

Detailed price information for Beone Medicines Ltd (ONC-Q) from The Globe and Mail including charting and trades.

SAN CARLOS, Calif. & REDWOOD CITY, Calif., August 10, 2026--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution

Tipranks Press Release.

Detailed price information for Beone Medicines Ltd (ONC-Q) from The Globe and Mail including charting and trades.

Detailed price information for Beone Medicines Ltd (ONC-Q) from The Globe and Mail including charting and trades.

BeOne Medicines (ONC) has an average rating of buy and mean price target of $425.22, according to an

BeOne Medicines (ONC) shares are trading at a discount to the company's fair value, and investors ar

BeOne Medicines (NASDAQ:ONC) reported second-quarter revenue of $1.7 billion, up 30% from a year earlier, and GAAP earnings per ADS of $2.05, up 144%, as sales of its BTK inhibitor BRUKINSA continued to expand across approved indications and global markets. Chief Executive Officer John Oyler said t

While the top- and bottom-line numbers for BeOne Medicines Ltd. - Sponsored ADR (ONC) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

BeOne Medicines (ONC) reported Q2 adjusted earnings Wednesday of $3.84 per diluted American deposita

SAN CARLOS, Calif., August 05, 2026--BeOne Medicines Ltd. announced financial results and corporate updates from the second quarter of 2026.

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for BeOne Medicines Ltd. - Sponsored ADR (ONC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.

The new investment increases BeOne Medicines’ total spend on US manufacturing facilities to over $1bn.

BeOne Medicines (NASDAQ:ONC) has announced a further $300 million investment to expand its manufacturing and research operations in Hopewell, New Jersey, increasing total spending at the Princeton West Innovation Campus to more than $1 billion. The project will significantly increase the site’s production capabilities while supporting future cancer drug development and creating new jobs.

BeOne Medicines (ONC) said Thursday it plans to invest $300 million to expand its flagship clinical